Updated:
Aerie Pharmaceuticals
Alcon successfully completes its acquisition of Aerie Pharmaceuticals, expanding its ophthalmic pharmaceutical portfolio with Rocklatan and Rhopressa and...
Aerie Pharmaceuticals
Alcon successfully completes its acquisition of Aerie Pharmaceuticals, expanding its ophthalmic pharmaceutical portfolio with Rocklatan and Rhopressa and adding significant R&D expertise in eye care.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Durham
Corporate office
Durham, NC, United States
Principals
David Endicott
CEO of Alcon
Sector focus
Frequently asked questions
What products did Aerie Pharmaceuticals develop?
Aerie developed Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution) for glaucoma, both FDA-approved. Its pipeline included AR-15512, a Phase 3 candidate for dry eye disease (per Business Wire, 2023).
How was Aerie Pharmaceuticals acquired?
Alcon completed the acquisition of Aerie in November 2023 for approximately $930 million in cash, funded with debt. The deal added Aerie's commercial products and R&D pipeline to Alcon's ophthalmic pharmaceutical division (per Business Wire, 2023).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: